Citius Oncology (CTOR) Liabilities and Shareholders Equity (2022 - 2026)

Citius Oncology (CTOR) has reported Liabilities and Shareholders Equity for 5 consecutive years, with $100.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 10.13% year-over-year to $100.7 million; the TTM figure through Mar 2026 stood at $403.3 million (up 27.84% YoY), while the FY2025 annual figure was $100.9 million, up 19.64% from the prior year.
• Liabilities and Shareholders Equity slipped to $100.7 million in Q1 2026 per CTOR's latest filing, from $110.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $110.0 million in Q4 2025 and bottomed at $47.7 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $78.2 million across 5 years, with a median of $78.5 million in 2023.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity retreated 29.57% — and 2025, when it soared 87.84%.
• Citius Oncology's Liabilities and Shareholders Equity stood at $68.2 million in 2022, then rose by 6.5% to $72.6 million in 2023, then advanced by 24.59% to $90.5 million in 2024, then gained by 21.54% to $110.0 million in 2025, then dropped by 8.43% to $100.7 million in 2026.
• Business Quant data shows CTOR's Liabilities and Shareholders Equity at $100.7 million in Q1 2026, $110.0 million in Q4 2025, and $100.9 million in Q3 2025.